Neurocrine Biosciences Inc. (NBIX)

85.42
0.58 0.68
NASDAQ : Health Technology
Prev Close 84.84
Open 85.64
Day Low/High 84.22 / 87.76
52 Wk Low/High 39.21 / 91.82
Volume 783.64K
Avg Volume 893.60K
Exchange NASDAQ
Shares Outstanding 88.49M
Market Cap 7.54B
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

3 Key Biotech Catalysts on the FDA Calendar

3 Key Biotech Catalysts on the FDA Calendar

A roundup of biotech names with actions pending at the FDA in coming weeks.

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Leerink Partners 7th Annual Global Healthcare Conference

Live Audio Webcast Will be on February 15, 2018

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Neurocrine Biosciences Announces Conference Call And Webcast Of Fourth Quarter And Year-End 2017 Financial Results

Conference Call and Webcast Scheduled for Tuesday, February 13

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

Neurocrine Biosciences Provides Preliminary Fourth Quarter And Full-Year 2017 Sales Results And 2018 Program Milestones

- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences To Present At The 36th Annual J.P. Morgan Healthcare Conference

Live Audio Webcast Will be on January 8, 2018

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

Neurocrine Biosciences Presents Long-term Data Analyses From Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms

- INGREZZA (valbenazine) Capsules Taken Once-daily Improved Tardive Dyskinesia Symptoms in Patients and was Generally Well Tolerated in 52-week Trial

Neurocrine Biosciences To Present At The 29th Annual Piper Jaffray Healthcare Conference

Neurocrine Biosciences To Present At The 29th Annual Piper Jaffray Healthcare Conference

Live Audio Webcast Will be on November 28, 2017

Neurocrine Biosciences To Present At The Jefferies 2017 London Healthcare Conference

Neurocrine Biosciences To Present At The Jefferies 2017 London Healthcare Conference

Live Audio Webcast Will be on November 16, 2017

Who Benefits From Tax Reform?

Who Benefits From Tax Reform?

Technology and biotech companies seem to be among the big winners.

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

Neurocrine Biosciences Soars on Third-Quarter Results -- Biotech Movers

The San Diego firm said net product sales of Ingrezza, a treatment for tardive dyskinesia, were $45.8 million during the quarter. The FDA approved Ingrezza in April.

AbbVie Announces Positive Phase 3 Extension Study Data For Investigational Oral Treatment Elagolix For Management Of Endometriosis With Associated Pain

AbbVie Announces Positive Phase 3 Extension Study Data For Investigational Oral Treatment Elagolix For Management Of Endometriosis With Associated Pain

- In two extension studies, elagolix demonstrated sustained reduction in average monthly menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse

Neurocrine Biosciences To Present At The Credit Suisse 26th Annual Healthcare Conference

Neurocrine Biosciences To Present At The Credit Suisse 26th Annual Healthcare Conference

Live Audio Webcast Will be on November 8, 2017

AbbVie Receives U.S. FDA Priority Review For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

AbbVie Receives U.S. FDA Priority Review For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

- FDA grants priority review to medicines it determines have potential to provide significant improvements in the safety and effectiveness of the treatment of a serious disease

Neurocrine Initiates Phase IIb Clinical Study Of Once-daily INGREZZA® In Children And Adolescents With Tourette Syndrome

Neurocrine Initiates Phase IIb Clinical Study Of Once-daily INGREZZA® In Children And Adolescents With Tourette Syndrome

12-Week T-Force GOLD Study to Assess the Safety, Tolerability, Efficacy and Optimal Dose of INGREZZA in Pediatric Patients

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2017 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Third Quarter 2017 Results

Conference Call and Webcast Scheduled for November 1, 2017

Neurocrine Announces FDA Approval Of 80 Mg INGREZZA® (valbenazine) Capsules For The Treatment Of Adults With Tardive Dyskinesia (TD)

Neurocrine Announces FDA Approval Of 80 Mg INGREZZA® (valbenazine) Capsules For The Treatment Of Adults With Tardive Dyskinesia (TD)

First and only TD therapy taken as one capsule, once per day; new 80 mg capsule expected to be available for patients within two weeks

Neurocrine Biosciences To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Neurocrine Biosciences To Present At The Morgan Stanley 15th Annual Global Healthcare Conference

Live Audio Webcast Will be on September 11, 2017

AbbVie Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

AbbVie Submits New Drug Application To U.S. FDA For Investigational Oral Treatment Elagolix For The Management Of Endometriosis With Associated Pain

- In clinical studies, elagolix demonstrated superiority compared to placebo in reducing three types of endometriosis-associated pain - daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse

Neurocrine Biosciences To Present At The Baird 2017 Global Healthcare Conference

Neurocrine Biosciences To Present At The Baird 2017 Global Healthcare Conference

Live Audio Webcast Will be on September 6, 2017

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2017 Results

Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2017 Results

Conference Call and Webcast Scheduled for August 3, 2017

TheStreet Quant Rating: D+ (Sell)